Patricia King, MD
Psychiatry · Chesapeake, VANPI 1114956638
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,700 of the $18,020 with a category attached, or 64.9%. AbbVie accounts for 72.5% of it on its own, with 23 other manufacturers making up the rest. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $49.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Johnson & Johnson$888
- Otsuka America Pharmaceutical, Inc.$631
- Alkermes, Inc.$501
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$466
- E.r. Squibb & Sons, L.L.C.$340
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$11,70065%
- Food & beverage$6,31235%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 111 | $13,072 |
| Johnson & Johnson | 44 | $888 |
| Otsuka America Pharmaceutical, Inc. | 34 | $631 |
| Alkermes, Inc. | 26 | $501 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $466 |
| E.r. Squibb & Sons, L.L.C. | 17 | $340 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $337 |
| Supernus Pharmaceuticals, Inc. | 17 | $302 |
| Teva Pharmaceuticals USA, Inc. | 11 | $195 |
| Lundbeck LLC | 9 | $179 |
| Neurocrine Biosciences, Inc. | 9 | $175 |
| Tris Pharma Inc | 8 | $147 |
| Jazz Pharmaceuticals Inc. | 6 | $119 |
| Almatica Pharma LLC | 6 | $109 |
| Axsome Therapeutics, Inc. | 4 | $101 |
| Bausch Health US, LLC | 4 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $84 |
| Eisai Inc. | 3 | $60 |
| Corium, LLC | 4 | $58 |
| Noven Therapeutics, LLC | 4 | $57 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Neos Therapeutics, LP | 1 | $17 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$11,700
How this compares
$18,020 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 69 | $96,798 |
| Invega SustennaPaliperidone Palmitate | 19 | $59,703 |
| CaplytaLumateperone Tosylate | 26 | $40,904 |
| Aripiprazole | 166 | $26,284 |
| SaphrisAsenapine Maleate | 12 | $24,644 |
| TrintellixVortioxetine Hydrobromide | 34 | $23,476 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,249 |
| Lurasidone Hcl | 34 | $13,025 |
| Paliperidone ErPaliperidone | 39 | $10,881 |
| Bupropion XlBupropion Hcl | 214 | $9,830 |
| Olanzapine | 139 | $7,501 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 60 | $4,767 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 99 | $4,739 |
| Chlorpromazine Hcl | 17 | $4,454 |
| Methylphenidate ErMethylphenidate Hcl | 31 | $4,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Saphris | $13,072 | $121,44281 claims |
| Johnson & JohnsonInvega Sustenna | $888 | $59,70319 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $466 | $40,90426 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $337 | $23,47634 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $31 | $17,24911 claims |
| Almatica Pharma LLCSertraline Hcl | $109 | $770134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Chesapeake
- Mona PatelChesapeake$9K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
- Robert GardellaStaunton$201K
- Timothy KaneStaunton$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.